Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179056 | 0.90 | EGLN1 (0.39) | PPARGF2EGLN1HDAC3HDAC1 | |
| SCHEMBL10179505 | 0.86 | MAPT (0.36) | EGLN1 | |
| SCHEMBL10181122 | 0.80 | EGLN1 (0.37) | EGLN1 | |
| SCHEMBL10180712 | 0.80 | TLR7 (0.41) | — | |
| SCHEMBL10180869 | 0.77 | EGLN1 (0.35) | EGLN1 | |
| SCHEMBL10180870 | 0.77 | EGLN1 (0.35) | EGLN1 | |
| SCHEMBL10179177 | 0.77 | EGLN1 (0.34) | EGLN1 | |
| SCHEMBL10181267 | 0.76 | FASN (0.37) | DHODH | |
| SCHEMBL10180121 | 0.75 | EGLN1 (0.41) | EGLN1 | |
| SCHEMBL10180087 | 0.75 | CCR2 (0.38) | HRH3DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | PPARG 128/4885F2 3264/4885EGLN1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.